An observational study in Heparin-induced Thrombocytopenia, sponsored by Société Française d'Anesthésie et de Réanimation. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-14.
Sponsored by Société Française d'Anesthésie et de Réanimation · Observational
Heparin-induced thrombocytopenia (HIT) is a rare but serious immune complication of heparin exposure that paradoxically increases the risk of thrombosis. In patients undergoing cardiac surgery with cardiopulmonary bypass (CPB), heparin is essential to prevent circuit clotting, yet contraindicated in HIT. Available alternatives carry significant limitations. Cangrelor, an intravenous reversible P2Y12 inhibitor, has shown promise in case reports and small series in this context, but no multicenter study exists. CATCH-IT is a multicenter retrospective observational study conducted across 11 French cardiac surgery centers, aiming to describe the safety and efficacy of cangrelor combined with heparin during CPB in confirmed HIT patients, by estimating the incidence of major bleeding and thrombotic events within 7 days after surgery.
Heparin-induced thrombocytopenia (HIT) is an immunological complication characterized by thrombocytopenia and a paradoxical pro-thrombotic state due to anti-platelet factor 4 (anti-PF4) antibodies. In patients requiring cardiopulmonary bypass (CPB), anticoagulation management is particularly challenging: unfractionated heparin is essential to prevent circuit thrombosis, yet its use is contraindicated when anti-PF4 antibodies are present. Alternative anticoagulants (bivalirudin, argatroban, danaparoid) carry important limitations including slow kinetics, absence of a reversal agent, high bleeding risk, and elevated cost.
Cangrelor, an intravenous reversible P2Y12 receptor inhibitor, offers rapid onset of action, full reversibility upon discontinuation, and no interaction with anti-PF4 antibodies. Its use during CPB in HIT patients has been reported in case reports and small series with favorable outcomes. However, no multicenter retrospective cohort study has yet characterized its real-world use, efficacy, or safety profile in this clinical context.
Given the low incidence of HIT in cardiac surgery and the complexity of the perioperative setting, a prospective randomized trial is not feasible. A multicenter retrospective study is therefore the most appropriate methodology to achieve sufficient sample size and reliably describe practice patterns, cangrelor dosing modalities, and thromboembolic and hemorrhagic complication profiles.
CATCH-IT will collect standardized data from existing medical records at 11 participating centers in France, covering patients operated between 2020 and 2025. No additional procedures or modifications to standard care are performed.
482 studies on the registry are indexed under Thrombocytopenia; 100 are open to participants now.
This study's planned enrollment of 132 is close to the median of 120 across 123 observational studies indexed under Thrombocytopenia.
Browse Thrombocytopenia studies →Société Française d'Anesthésie et de Réanimation is the lead sponsor of 18 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Incidence of major hemorrhagic and/or thrombotic events
Proportion of patients experiencing at least one major hemorrhagic event (BARC grade ≥3, including hemoglobin drop ≥3 g/dL, red blood cell transfusion attributed to bleeding, need for interventional procedure, hemorrhagic shock, or documented intracranial hemorrhage) and/or thrombotic complication (imaging-confirmed ischemic stroke, acute mesenteric ischemia requiring surgery, acute limb ischemia, or vascular thrombosis) within 7 days after surgery.
Time frame: 7 days postoperatively
Cangrelor dosing modalities
Description of dose used during CPB (cardiopulmonary bypass)
Time frame: intraoperative period.
Cangrelor dosing modalities
Description monitoring during CPB (cardiopulmonary bypass)
Time frame: intraoperative period.
Cangrelor dosing modalities
Description of dose adjustments during CPB (cardiopulmonary bypass)
Time frame: intraoperative period.
Cangrelor dosing modalities
Description of duration of drug during CPB (cardiopulmonary bypass)
Time frame: intraoperative period.
Platelet count
Serial measurements
Time frame: from surgery to postoperative day 7.
Hemoglobin level
Serial measurements
Time frame: from surgery to postoperative day 7.
Fibrinogen level
Serial measurements
Time frame: from surgery to postoperative day 7.
Prothrombin time (PT) and activated partial thromboplastin time (aPTT)
Serial measurements
Time frame: from surgery to postoperative day 7.
Transfusion requirements
Type and number of blood products (packed red blood cells, platelets, fresh frozen plasma) and plasma-derived medicinal products administered
Time frame: intraoperative period to postoperative day 7.
Duration of mechanical ventilation
follow the duration of mechanical ventilation
Time frame: From initiation of mechanical ventilation until successful weaning, assessed up to a maximum of 90 days
Hospital length of stay
follow the duration of the hospitalisation
Time frame: From date of hospital admission until date of hospital discharge, assessed up to a maximum of 90 day
In-hospital mortality
verify if partient died or not
Time frame: From date of hospital admission until date of hospital discharge, assessed up to a maximum of 90 day
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Société Française d'Anesthésie et de Réanimation